You are here:

Creon micro (Creon®)


Following an abbreviated submission

New formulation for infants

Creon microgranule formulation is accepted for restricted use in NHS Scotland for the treatment of pancreatic exocrine insufficiency. It provides a formulation suitable for use in young infants and is expected to be used for young cystic fibrosis sufferers who are unable to swallow capsules. The associated resource implications are expected to be small.

Drug Details

Drug Name: Creon micro (Creon®)
SMC Drug ID: 141/04
Manufacturer: Solvay Healthcare Ltd
Indication: Pancreatic exocrine insufficiency
BNF Category:
Sub Category: 1.9 Drugs affecting intestinal secretions
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 13 December 2004